Literature DB >> 9846698

The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily.

C Madry1, Y Laabi, I Callebaut, J Roussel, A Hatzoglou, M Le Coniat, J P Mornon, R Berger, A Tsapis.   

Abstract

The BCMA gene is a new gene discovered by the molecular analysis of a t(4;16) translocation, characteristic of a human T cell lymphoma. It has no significant similarity with any known protein or motif, so that its function was unknown. This report describes the cloning of murine BCMA cDNA and its genomic counterpart. The mouse gene is organized into three exons, like the human gene, and lies in murine chromosome 16, in the 16B3 band, the counterpart of the human chromosome 16p13 band, where the human gene lies. Murine BCMA cDNA encodes a 185 amino acids protein (184 residues for the human), has a potential central transmembrane segment like the human protein and is 62% identical to it. The murine BCMA mRNA is found mainly in lymphoid tissues, as is human BCMA mRNA. Alignment of the murine and human BCMA protein sequences revealed a conserved motif of six cysteines in the N-terminal part, which strongly suggests that the BCMA protein belongs to the tumor necrosis factor receptor (TNFR) superfamily. Human BCMA is the first member of the TNFR family to be implicated in a chromosomal translocation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9846698     DOI: 10.1093/intimm/10.11.1693

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  40 in total

1.  B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses.

Authors:  S Xu; K P Lam
Journal:  Mol Cell Biol       Date:  2001-06       Impact factor: 4.272

2.  Impaired IgA class switching in APRIL-deficient mice.

Authors:  Emanuela Castigli; Sumi Scott; Fatma Dedeoglu; Paul Bryce; Haifa Jabara; Atul K Bhan; Emiko Mizoguchi; Raif S Geha
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-26       Impact factor: 11.205

3.  A soluble BAFF antagonist, BR3-Fc, decreases peripheral blood B cells and lymphoid tissue marginal zone and follicular B cells in cynomolgus monkeys.

Authors:  Yulia Vugmeyster; Dhaya Seshasayee; Wesley Chang; Anahid Storn; Kathy Howell; Susan Sa; Tenea Nelson; Flavius Martin; Iqbal Grewal; Ellen Gilkerson; Ben Wu; Jeff Thompson; Barbara N Ehrenfels; Song Ren; An Song; Thomas R Gelzleichter; Dimitry M Danilenko
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

4.  FcgammaRIIB signals inhibit BLyS signaling and BCR-mediated BLyS receptor up-regulation.

Authors:  Jenni E Crowley; Jason E Stadanlick; John C Cambier; Michael P Cancro
Journal:  Blood       Date:  2008-09-12       Impact factor: 22.113

5.  B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia.

Authors:  Sherine F Elsawa; Anne J Novak; Deanna M Grote; Steven C Ziesmer; Thomas E Witzig; Robert A Kyle; Stacey R Dillon; Brandon Harder; Jane A Gross; Stephen M Ansell
Journal:  Blood       Date:  2005-11-22       Impact factor: 22.113

Review 6.  Regulatory roles of the tumor necrosis factor receptor BCMA.

Authors:  Christine M Coquery; Loren D Erickson
Journal:  Crit Rev Immunol       Date:  2012       Impact factor: 2.214

Review 7.  TNF revisited: osteoprotegerin and TNF-related molecules in heart failure.

Authors:  Thor Ueland; Arne Yndestad; Christen P Dahl; Lars Gullestad; Pål Aukrust
Journal:  Curr Heart Fail Rep       Date:  2012-06

8.  A BAFF-R mutation associated with non-Hodgkin lymphoma alters TRAF recruitment and reveals new insights into BAFF-R signaling.

Authors:  Joanne M Hildebrand; Zhenghua Luo; Michelle K Manske; Tammy Price-Troska; Steven C Ziesmer; Wai Lin; Bruce S Hostager; Susan L Slager; Thomas E Witzig; Stephen M Ansell; James R Cerhan; Gail A Bishop; Anne J Novak
Journal:  J Exp Med       Date:  2010-11-01       Impact factor: 14.307

9.  Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin lymphoma.

Authors:  Anne J Novak; Susan L Slager; Zachary S Fredericksen; Alice H Wang; Michelle M Manske; Steven Ziesmer; Mark Liebow; William R Macon; Stacey R Dillon; Thomas E Witzig; James R Cerhan; Stephen M Ansell
Journal:  Cancer Res       Date:  2009-04-21       Impact factor: 12.701

10.  APRIL-deficient mice have normal immune system development.

Authors:  Eugene Varfolomeev; Frank Kischkel; Flavius Martin; Dhaya Seshasayee; Hua Wang; David Lawrence; Christine Olsson; Lucrece Tom; Sharon Erickson; Dorothy French; Peter Schow; Iqbal S Grewal; Avi Ashkenazi
Journal:  Mol Cell Biol       Date:  2004-02       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.